AIM:NYSEAMERICAN
AIM ImmunoTech Inc
US$0,28
arrow_downward
-5,41%(-0,016) 1D
US$0,28
arrow_upward
+1,57% (+0,0044)bedtimeAfter hours
Closed: 2 ກ.ລ., 16 ໂມງ 0 ນາທີ 00 ວິນາທີ GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for AIM...
Open
US$0,30
High
US$0,31
Low
US$0,28
Mkt. cap
໗,໖໖ ລ້ານ
Avg. vol.
໔໐,໙໕ ລ້ານ
Volume
໙໘໓,໑໒ ພັນ
52-wk high
US$20,33
52-wk low
US$0,21
EPS
US$-7,39
Beta
໑,໒໐
Shares outstanding
໒໗,໗໒ ລ້ານ
No. of employees
໒໐
Open
US$0,30
High
US$0,31
Low
US$0,28
Mkt. cap
໗,໖໖ ລ້ານ
Avg. vol.
໔໐,໙໕ ລ້ານ
Volume
໙໘໓,໑໒ ພັນ
52-wk high
US$20,33
52-wk low
US$0,21
EPS
US$-7,39
Beta
໑,໒໐
Shares outstanding
໒໗,໗໒ ລ້ານ
No. of employees
໒໐
News stories
From sources across the web
NewsCord
·
7 ນາທີກ່ອນ
Bending Spoons Prices Nasdaq IPO at $29, Raises $1.68 Billion: 16 Sources (Western Mainstream: 4)
Yahoo Finance
·
37 ນາທີກ່ອນ
Stock market today: S&P 500, Nasdaq, Dow futures climb after record-setting week
Fortune
·
3 ຊົ່ວໂມງກ່ອນ
Stock market outlook: S&P 500 to lose much of 2026 gains as 'speculation is hitting extreme levels'
Investor's Business Daily
·
1 ຊົ່ວໂມງກ່ອນ
Dow Jones Futures: Techs Jump With Apple, SpaceX, Sandisk, Robinhood In Focus
Profile
AIM ImmunoTech Inc., formerly known as Hemispherx Biopharma Inc., is a biopharmaceutical company based in Ocala, Florida that is focused on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Founded in 1990, the company has twenty-three employees.
The company has created an immunomodulatory double stranded RNA drug called Ampligen.
It is also developing Ampligen to use as a treatment for multiple cancer tumor types, COVID-19 and chronic fatigue syndrome. Wikipedia
About AIM ImmunoTech Inc
CEO-
Employees20
Founded1966
Headquartersຟິລາເດເຟຍ, ເພນຊີນວາເນຍ, ສະຫະລັດ
SectorBiotechnology
Websiteaimimmuno.com
AI content may include mistakes. Learn more